Amphera is a late-stage biotechnology company developing cell therapies to treat cancer. MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.
| Website | https://www.amphera.nl |
| Revenue | $5.8 million |
| Employees | 3 (0 on RocketReach) |
| Founded | 2012 |
| Industry | Biotechnology, Business Services General, Discovery Tools (Healthcare), Business Services |
| Keywords | Cell Therapy, Cancer Treatment, Oncology, Biotechnology, Immunotherapy, Autologous Cell Therapy, Cancer Immunotherapy, Cell Therapies, Clinical Trials, Pharmaceutical Research, Drug Development, Biopharma, Regenerative Medicine, Precision Medicine, Advanced Therapies, Biologics, Therapeutic Vaccines |
| Competitors | Thermo Fisher Scientific, Merck Group, Agilent Technologies, Illumina, PerkinElmer, Inc., Waters Corporation, Bio-Rad Laboratories, Bruker, Repligen Corporation, Eppendorf Group +44 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541713 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies |
Looking for a particular Amphera B.V. employee's phone or email?
Amphera B.V. Questions
The Amphera B.V. annual revenue was $5.8 million in 2026.
Amphera B.V. is based in 's-Hertogenbosch, Noord-Brabant.
The NAICS codes for Amphera B.V. are [541713, 5417, 54, 541, 54171].
The SIC codes for Amphera B.V. are [87, 873].
Related Companies
